Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model

Cancer Prevention Research

Volumn 4, Issue 12, 2011, Pages 2122-2130

  Ru, Peng ^a   Steele, Robert ^a   Nerurkar, Pratibha V ^b   Phillips, Nancy ^a   Ray, Ratna B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF HAWAII AT MANOA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN E; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MOMORDICA CHARANTIA EXTRACT; PROTEIN BAX; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, TRANSGENIC; MOMORDICA CHARANTIA; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 83055174654     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0376     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistic. CA Cancer J Clin 2009;59:225-49.
2. Albertsen P. Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice? Cancer 2008;112:1-3.
3. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005;23:1-9. (Pubitemid 40425164)
4. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
5. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol 2002;81:81-100. (Pubitemid 34518472)
6. Jayasooriya AP, Sakono M, Yukizaki C, Kawano M, Yamamoto K, Fukuda N. Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J Ethnopharmacol 2000;72:331-6.
7. Chao CY, Huang CJ. Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. J Biomed Sci 2003;10:782-91.
8. Chen Q, Chan LL, Li ET. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr 2003;133:1088-93. (Pubitemid 36407130)
9. Nerurkar PV, Lee YK, Motosue M, Adeli K, Nerurkar VR. Momordica charantia (bitter melon) reduces plasma apolipoprotein B-100 and increases hepatic insulin receptor substrate and phosphoinositide-3 kinase interactions. Br J Nutr 2008;100:751-9.
10. Nerurkar PV, Lee YK, Nerurkar VR. Momordica charantia (bitter melon) inhibits primary human adipocyte differentiation by modulating adipogenic genes. BMC Complement Altern Med 2010:10:34.
11. Nerurkar PV, Lee YK, Linden EH, Lim S, Pearson L, Frank J, et al. Lipid lowering effects of Momordica charantia (bitter melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2. Br J Pharmacol 2006;148:1156-64. (Pubitemid 44223021)
12. Jilka C, Strifler B, Fortner GW, Hays EF, Takemoto DJ. In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Res 1983;43:5151-5. (Pubitemid 14227492)
13. Lee-Huang S, Huang PL, Sun Y, Chen HC, Kung HF, Huang PL, et al. Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. Anticancer Res 2000;20:653-9. (Pubitemid 30240615)
14. Li M, Chen Y, Liu Z, Shen F, Bian X, Meng Y. Anti-tumor activity and immunological modification of ribosome-inactivating protein (RIP) from Momordica charantia by covalent attachment of polyethylene glycol. Acta Biochim Biophys Sin (Shanghai) 2009;41:792-9.
15. Kohno H, Suzuki R, Noguchi R, Hosokawa M, Miyashita K, Tanaka T. Dietary conjugated linolenic acid inhibits azoxymethane-induced colonic aberrant crypt foci in rats. Jpn J Cancer Res 2002;93: 133-42. (Pubitemid 34223756)
16. Nagasawa H, Watanabe K, Inatomi H. Effects of bitter melon (Momordica charantia l.) or ginger rhizome (Zingiber offifinale rosc) on spontaneous mammary tumorigenesis in SHN mice. Am J Chin Med 2002;30:195-205. (Pubitemid 41758893)
17. Tsuzuki T, Tokuyama Y, Igarashi M, Miyazawa T. Tumor growth suppression by alpha-eleostearic acid, a linolenic acid isomer with a conjugated triene system, via lipid peroxidation. Carcinogenesis 2004;25:1417-25. (Pubitemid 39162707)
18. Ghosh AK, Steele R, Ray RB. c-myc promoter-binding protein 1 (MBP- 1) regulates prostate cancer cell growth by inhibiting MAPK pathway. J Biol Chem 2005;280:14325-30. (Pubitemid 40517336)
19. Ray RB, Raychoudhuri A, Steele R, Nerurkar P. Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res 2010;70:1925-31.
20. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-91. (Pubitemid 27468967)
21. Klein RD, Kant JA. Opportunity knocks: the pathologist as laboratory genetics consultant. Arch Pathol Lab Med 2006;130:1603-4. (Pubitemid 44683786)
22. Gupta S, Hastak K, Ahmad N, Lewin JS, Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci U S A 2001;98:10350-5. (Pubitemid 32803023)
23. Raina K, Singh RP, Agarwal R, Agarwal C. Oral grape seed extract inhibits prostate tumor growth and progression in TRAMP mice. Cancer Res 2007;67:5976-82. (Pubitemid 46985034)
24. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2007;67:11083-91. (Pubitemid 350145939)
25. Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, Arlotti JA, et al. Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. Cancer Res 2009;69:2117-25.
26. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-305. (Pubitemid 38339483)
27. Park KS, Ahn Y, Kim JA, Yun MS, Seong BL, Choi KY. Extracellular zinc stimulates ERK-dependent activation of p21(Cip/WAF1) and inhibits proliferation of colorectal cancer cells. Br J Pharmacol 2002;137:597-607 (Pubitemid 35333085)
28. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.
29. Mukhopadhyay I, Sausville EA, Doroshow JH, Roy KK. Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways. J Biol Chem 2006;281: 37330-44. (Pubitemid 46042037)
30. Robertson BW, Bonsal L, Chellaiah MA. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells. Mol Cancer 2010;9:260.
31. Xia W, Spector S, Hardy L, Zhao S, Saluk A, Alemane L, et al. Tumor selective G2/M cell cycle arrest and apoptosis of epithelial and hematological malignancies by BBL22, a benzazepine. Proc Natl Acad Sci U S A 2000;97:7494-9. (Pubitemid 30431491)
32. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
33. Denmeade SR, Isaacs JT. Programmed cell death (apoptosis) and cancer chemotherapy. Cancer Control 1996;3:303-309. (Pubitemid 26302008)
34. Kaur M, Agarwal C, Agarwal R. Anticancer and cancer chemopreventive potential of grape seed extract and other grape-based products. J Nutr 2009;139:1806S-12S.
35. Khan N, Afaq F, Mukhtar H. Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis 2007;28:233-9. (Pubitemid 46321838)
36. Nerurkar P, Ray RB. Bitter melon: antagonist to cancer. Pharm Res 2010;27:1049-53.
37. Zhu H, Zhang L, Wu S, Teraishi F, Davis JJ, Jacob D, et al. Induction of S-phase arrest and p21 overexpression by a small molecule 2[[3-(2,3- dichlorophenoxy)propyl] amino]ethanol in correlation with activation of ERK. Oncogene 2004;23:4984-92. (Pubitemid 38938731)
38. Rahman KW, Li Y, Wang Z, Sarkar SH, Sarkar FH. Gene expression profiling revealed survivin as a target of 3,3′-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells. Cancer Res 2006;66:4952-60.
39. Choi S, Kim TW, Singh SV. Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases. Pharm Res 2009;26:2280-8.
40. Kobatake T, Yano M, Toyooka S, Tsukuda K, Dote H, Kikuchi T, Toyota M, et al. Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep 2004;12:1087-92.
41. Todd DE, Densham RM, Molton SA, Balmanno K, Newson C, Weston CR, et al. ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest. Oncogene 2004;23:3284-95. (Pubitemid 38669818)
42. Edlund S, Bu S, Schuster N, Aspenström P, Heuchel R, Heldin NE, et al. Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell 2003;14:529-44. (Pubitemid 36237014)
43. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading toG1 cell cycle arrest. J Biol Chem 2006;281:39480-91. (Pubitemid 46041908)
44. Moro L, Arbini AA, Marra E, Greco M. Constitutive activation of MAPK/ ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2. Int J Oncol 2007;30:217-24.